Pharma Stock; The Indian Pharma Market became healthy in 9.3% year during the month of March. CiplaSun Pharmaceutical Industries, IPCA laboratories Ltd., JB Chemicals and Pharmaceuticals Limited (JB Pharma), Glenmark pharmaceuticals During the month of March 2025, Limited was the leading driver of Indian Pharma Market Growth.
Pharma market outperformer
In March 2025, according to top -20 pharma companies Motel Oswal Financial ServicesOn the other hand, IPCA laboratories marked the growth of 14.3% yoy. All these firms recorded a higher growth rate than the Indian Pharma market. Other outperforms were Sun Pharmaceutical Industries and Glenmark Pharmaceuticals. Sun Pharmaceuticals marked the growth of 12.6% year on the year and Glenmark Pharmaceuticals were among the major drivers of the Indian Pharma Markets (IPM), which was better than IPM development.
The growth of IPM, which performed better than IPCA, led to a strong double -digit increase in major treatments such as pain relief, cardiology, cardiology, antinoplasts and gastro, according to Motelle Oswal Finrical Services. JB chemicals, on the other hand, were led under the leadership of a strong show in ophthalmology and gastro. Cipla improved IPM, which is inspired by double-digit increase in cardiac, anti-dibitic and urology segment
Other major trends
During the month of March 2025, the growth of the Indian Pharma market was healthy given the fact that during the month of March 2024, IPM growth was only 1% and 4.1% in the month of February 2025.
In March 2025, the acute therapy growth was 8% healthy 8%, which was much stronger than 1% in the month of March 2024 and 3% in the month of February 2025, which was held responsible for the mood by analysts by analysts.
By March 2025, Indian pharma companies hold a majority stake of 83% in IPM, while the remaining MOFSL is conducted by multi-national pharma companies (MNCs). Nevertheless, in March 255, Indian companies increased by 9%, while MNCs increased by 10.4% yoy.
Disclaimer: The views and recommendations made above are of individual analysts or broking companies, not Mint. We recommend investors to check with certified experts before taking any investment decisions.
